IMMUNOGLOBULIN VARIANTS AND USES THEREOF

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases. 181-. (canceled)82: An isolated nucleic acid encoding an antibody that binds to human CD20 or an antigen-binding fragment thereof , wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution S92A.83: A vector comprising the nucleic acid of .84: An isolated host cell comprising the nucleic acid of .85: An isolated host cell comprising the vector of .86: An isolated host cell comprising a first vector comprising a nucleic acid encoding the heavy chain variable region (VH) of an antibody or antigen-binding fragment thereof claim 83 , and a second vector comprising a nucleic acid encoding the light chain variable region (VL) of the antibody or antigen-binding fragment thereof claim 83 , wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution S92A; and wherein the antibody binds to human CD20.87: A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof claim 84 , encoded by the nucleic acid present in the host cell of claim 84 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.88: A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof claim 85 , encoded by the nucleic acid in the vector present in the host cell of claim 85 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.89: A method ...

ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same. 1348-. (canceled)349. A method of treating an IL-33 mediated disorder in a subject in need thereof , the method comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds IL-33 , wherein the antibody comprises a binding domain comprising the following six HVRs:{'sub': 1', '1, '(a) an HVR-H1 comprising the amino acid sequence of SFSXS (SEQ ID NO: 62), wherein Xis Met, Leu, or Val;'}{'sub': 1', '1, '(b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDXVKG (SEQ ID NO: 63), wherein Xis Ser or Ala;'}{'sub': 1', '2', '1', '2, '(c) an HVR-H3 comprising the amino acid sequence of ANYGXXFFEV (SEQ ID NO: 64), wherein Xis Asn or Asp, and Xis Trp or Phe;'}(d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4);(e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO: 5); and(f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO: 6).350. The method of claim 349 , wherein the IL-33-mediated disorder is an ophthalmologic disorder claim 349 , an inflammatory condition claim 349 , an immune disorder claim 349 , a fibrotic disorder claim 349 , an eosinophilic disorder claim 349 , an infection claim 349 , pain claim 349 , a central nervous system disorder claim 349 , or a solid tumor.351. The method of claim 350 , wherein: (a) wet AMD, dry AMD, or geographic atrophy (GA), or', '(b) intermediate AMD or advanced AMD;, '(i) the ophthalmologic disorder is AMD, or wherein the ophthalmologic disorder is'} (a) diabetic retinopathy (DR) or retinopathy of prematurity (ROP); or', '(b) high-altitude DR; or, '(ii) the ophthalmologic disorder is retinopathy of the eye, or wherein the ophthalmologic disorder is'} (a) infectious conjunctivitis or non-infectious conjunctivitis; or', '(b) allergic conjunctivitis., '(iii) the ophthalmologic disorder is conjunctivitis, or wherein the ...

ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. 153.-. (canceled)54. An isolated nucleic acid encoding an anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:178;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:179;(c) HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:180 and 181;(d) HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:182, 183, 184, 185, and 186;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:187; and(f) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:188, 189, and 190.55. The isolated nucleic acid of claim 54 , wherein the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:113 claim 54 , 117 claim 54 , 119 claim 54 , 122 claim 54 , 124 claim 54 , 126 claim 54 , 128 claim 54 , 130 claim 54 , and 132.56. The isolated nucleic acid of claim 54 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:111 and 115.57. The isolated nucleic acid of claim 54 , wherein the antibody comprises a heavy chain variable region and a light chain variable region claim 54 , wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:111 and 115 claim 54 , and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:113 claim 54 , 117 claim 54 , 119 claim 54 , 122 claim 54 , 124 claim 54 , 126 claim 54 , 128 claim 54 , 130 claim 54 , and 132.58. The ...

IMMUNOGLOBULIN VARIANTS AND USES THEREOF

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases. 181-. (canceled)82: An isolated nucleic acid encoding an antibody that binds to human CD20 or an antigen-binding fragment thereof , wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution S92A.83: A vector comprising the nucleic acid of .84: An isolated host cell comprising the nucleic acid of .85: An isolated host cell comprising the vector of .86: An isolated host cell comprising a first vector comprising a nucleic acid encoding the heavy chain variable region (VH) of an antibody or antigen-binding fragment thereof claim 83 , and a second vector comprising a nucleic acid encoding the light chain variable region (VL) of the antibody or antigen-binding fragment thereof claim 83 , wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution S92A; and wherein the antibody binds to human CD20.87: A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof claim 84 , encoded by the nucleic acid present in the host cell of claim 84 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.88: A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof claim 85 , encoded by the nucleic acid in the vector present in the host cell of claim 85 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.89: A method ...

ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. 1. An isolated anti-hemagglutinin antibody comprising three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:191 and 192;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:193;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:194;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:195;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:196; and(f) HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:197, 198, and 199.2. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 136 claim 1 , 140 claim 1 , 144 claim 1 , 146 claim 1 , 150 claim 1 , 152 claim 1 , and 235.3. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 134 claim 1 , 138 claim 1 , 142 claim 1 , 148 claim 1 , and 234.4. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a heavy chain variable region and a light chain variable region claim 1 , wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:134 claim 1 , 138 claim 1 , 142 claim 1 , 148 claim 1 , and 234 claim 1 , and the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:136 claim 1 , 140 claim 1 , 144 claim 1 , 146 claim 1 , 150 claim 1 , 152 claim 1 , and 235.5. The isolated anti-hemagglutinin antibody of ...

ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same. 1348-. (canceled)349. An isolated nucleic acid encoding an antibody that specifically binds IL-33 , wherein the antibody comprises a binding domain comprising the following six HVRs:{'sub': 1', '1, '(a) an HVR-H1 comprising the amino acid sequence of SFSXS (SEQ ID NO: 62), wherein Xis Met, Leu, or Val;'}{'sub': 1', '1, '(b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDXNKG (SEQ ID NO: 63), wherein Xis Ser or Ala;'}{'sub': 1', '2', '1', '2, '(c) an HVR-H3 comprising the amino acid sequence of ANYGXXFFEV (SEQ ID NO: 64), wherein Xis Asn or Asp, and Xis Trp or Phe;'}(d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4);(e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO: 5); and(f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO: 6).350. The nucleic acid of claim 349 , wherein the binding domain comprises the following six HVRs:(a) an HVR-H1 comprising the amino acid sequence of SFSMS (SEQ ID NO: 1);(b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDSVKG (SEQ ID NO: 2);(c) an HVR-H3 comprising the amino acid sequence of ANYGNWFFEV (SEQ ID NO: 3);(d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4);(e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO: 5); and(f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO: 6).351. The nucleic acid of claim 349 , wherein the antibody specifically binds human or cynomolgus monkey (cyno) IL-33.352. The nucleic acid of claim 351 , wherein the antibody specifically binds both human and cyno IL-33.353. The nucleic acid of claim 352 , wherein the antibody specifically binds both human and cyno IL-33 with a Kof about 1 nM or lower.354. The nucleic acid of claim 353 , wherein the antibody specifically binds human IL-33 with a Kbetween about 1 pM and about 500 pM.355. The nucleic acid of ...

IMMUNOGLOBULIN VARIANTS AND USES THEREOF

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases. 181-. (canceled)82. An isolated nucleic acid encoding an antibody that binds to human CD20 or an antigen-binding fragment thereof , wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution S92A.83. A vector comprising the nucleic acid of .84. An isolated host cell comprising the nucleic acid of .85. An isolated host cell comprising the vector of .86. An isolated host cell comprising a first vector comprising a nucleic acid encoding the heavy chain variable region (VH) of an antibody or antigen-binding fragment thereof claim 83 , and a second vector comprising a nucleic acid encoding the light chain variable region (VL) of the antibody or antigen-binding fragment thereof claim 83 , wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO:8 with amino acid substitutions D56A and N100A and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:2 with amino acid substitution S92A; and wherein the antibody binds to human CD20.87. A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof claim 84 , encoded by the nucleic acid present in the host cell of claim 84 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.88. A method of producing an antibody that binds to human CD20 or an antigen-binding fragment thereof 85 , encoded by the nucleic acid in the vector present in the host cell of claim 85 , comprising culturing the host cell under suitable conditions so that the antibody or antigen-binding fragment thereof is produced.89. A method of ...

ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. 153-. (canceled)54. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition comprising an anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin , wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:178;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:179;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:181;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:183;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:187; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:189,thereby treating, inhibiting, or preventing influenza A virus infection.55. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition comprising an anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin , wherein the antibody comprises a heavy chain variable region and a light chain variable region , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:115 , and the light chain variable region comprises the amino acid sequence of SEQ ID NO:117 , thereby treating , inhibiting , or preventing influenza A virus infection.56. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition ...

ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same. 1. An isolated antibody that specifically binds both human and cynomolgus monkey (cyno) interleukin-33 (IL-33) with a Kof about 500 pM or lower , inhibits the binding of human IL-33 to an IL-33 receptor with 90% inhibitory concentration (IC90) of between about 0.001 μg/mL and about 0.5 μg/mL and with a 50% inhibitory concentration (IC50) of between about 800 fM and about 10 pM , and inhibits the binding of cyno IL-33 to an IL-33 receptor with an IC50 of between about 1 nM and about 5 nM.222-. (canceled)23. The antibody of claim 1 , wherein the antibody comprises a binding domain comprising:(a) an HVR-H1 comprising the amino acid sequence of SFSMS (SEQ ID NO: 1);(b) an HVR-H2 comprising the amino acid sequence of TISGGKTFTDYVDSVKG (SEQ ID NO: 2);(c) an HVR-H3 comprising the amino acid sequence of ANYGNWFFEV (SEQ ID NO: 3);(d) an HVR-L1 comprising the amino acid sequence of RASESVAKYGLSLLN (SEQ ID NO: 4);(e) an HVR-L2 comprising the amino acid sequence of AASNRGS (SEQ ID NO: 5); and(f) an HVR-L3 comprising the amino acid sequence of QQSKEVPFT (SEQ ID NO: 6).2430-. (canceled)31. The antibody of claim 1 , wherein the antibody comprises a binding domain comprising:(a) an HVR-H1 comprising the amino acid sequence of SSIFYWG (SEQ ID NO: 65);(b) an HVR-H2 comprising the amino acid sequence of SIYYSGRTYYNPSLKS (SEQ ID NO: 66) or SIYYSGRTYYNPALKS (SEQ ID NO: 67);(c) an HVR-H3 comprising the amino acid sequence of AGGLYNWNDESFSFYMDV (SEQ ID NO: 68);(d) an HVR-L1 comprising the amino acid sequence of RASQSFSSSYLA (SEQ ID NO: 69);(e) an HVR-L2 comprising the amino acid sequence of GASSRAT (SEQ ID NO: 70); and(f) an HVR-L3 comprising the amino acid sequence of QQYDRSPLT (SEQ ID NO: 71).3236-. (canceled)37. An isolated antibody that specifically binds IL-33 claim 1 , wherein the antibody comprises a binding domain comprising the following six HVRs:(a) an HVR-H1 comprising the amino acid ...

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF

The invention provides anti-IL-4 antibodies and bispecific antibodies and methods of using the same. 1. A multispecific antibody comprising an antigen-binding domain that comprises a first VH/VL unit that specifically binds IL-4 and a second VH/VL unit that specifically binds IL-13 , wherein the antibody:a) inhibits binding of IL-4 to IL-4 receptor alpha (IL-4Rα),b) inhibits IL-4-induced proliferation of cells in vitro, and/orc) inhibits IL-13-induced proliferation of cells in vitro.2. The multispecific antibody of claim 1 , wherein the first VH/VL unit comprises HVR-H3 comprising the amino acid sequence of SEQ ID NO: 14 claim 1 , HVR-L3 comprising the amino acid sequence of SEQ ID NO: 17 claim 1 , and HVR-H2 comprising the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 18.3. The multispecific antibody of or claim 1 , wherein the first VH/VL unit comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 12 claim 1 , HVR-H2 comprising the amino acid sequence of SEQ ID NO: 13 or SEQ ID NO: 18 claim 1 , and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 14.4. The multispecific antibody of any one of to claim 1 , wherein the first VH/VL unit comprises HVR-L1 comprising the amino acid sequence of SEQ ID NO: 15 claim 1 , HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16 claim 1 , and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 17.5. The multispecific antibody of any one of to claim 1 , wherein the first VH/VL unit comprises (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 9; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 10; or (c) a VH sequence as in (a) and a VL sequence as in (b).6. The multispecific antibody of any one of to claim 1 , wherein the first VH/VL unit comprises a VH sequence selected from SEQ ID NOs: 1 and 3 to 9.7. The multispecific antibody of any one of to claim 1 , wherein the first VH/VL unit comprises a VL ...

ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same. 1. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition comprising an anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin , wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:191;(b) HVR-H2 comprises the amino acid sequence of SEQ ID NO:193;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:194;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:195;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:196; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:197,thereby treating, inhibiting, or preventing influenza A virus infection in the individual.2. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount of a composition comprising an anti-hemagglutinin monoclonal antibody that specifically binds influenza A virus hemagglutinin , wherein the antibody comprises a heavy chain variable region and a light chain variable region , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:234 , and the light chain variable region comprises the amino acid sequence of SEQ ID NO:235 , thereby treating , inhibiting , or preventing influenza A virus infection in the individual.3. A method for treating , inhibiting , or preventing influenza A virus infection in an individual in need thereof , the method comprising administering to the individual an effective amount ...

ANTI-INFLUENZA B VIRUS HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same. 1. An isolated anti-hemagglutinin monoclonal antibody that specifically binds influenza B virus hemagglutinin comprising three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:63;(b) HVR-H2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:67, 68, 69, 70, 71, 72, 73, and 74;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:77;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:56;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:58; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:60.2. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:91.3. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:92 claim 1 , 95 claim 1 , 97 claim 1 , 99 claim 1 , 101 claim 1 , 103 claim 1 , 105 claim 1 , and 107.4. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region and a heavy chain variable region claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:91 claim 1 , and the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:92 claim 1 , 95 claim 1 , 97 claim 1 , 99 claim 1 , 101 claim 1 , 103 claim 1 , 105 claim 1 , and 107.5. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID ...

ANTI-INFLUENZA B VIRUS HEMAGGLUTININ ANTIBODIES AND METHODS OF USE

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same. 1. An isolated anti-hemagglutinin monoclonal antibody that specifically binds influenza B virus hemagglutinin , wherein the antibody comprises three heavy chain hypervariable regions (HVR-H1 , HVR-H2 , and HVR-H3) and three light chain hypervariable regions (HVR-L1 , HVR-L2 , and HVR-L3) , wherein:(a) HVR-H1 comprises the amino acid sequence of SEQ ID NO:63;(b) HVR-H2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:67, 68, 69, 70, 71, 72, 73, and 74;(c) HVR-H3 comprises the amino acid sequence of SEQ ID NO:77;(d) HVR-L1 comprises the amino acid sequence of SEQ ID NO:56;(e) HVR-L2 comprises the amino acid sequence of SEQ ID NO:58; and(f) HVR-L3 comprises the amino acid sequence of SEQ ID NO:60.2. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:91.3. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:92 claim 1 , 95 claim 1 , 97 claim 1 , 99 claim 1 , 101 claim 1 , 103 claim 1 , 105 claim 1 , and 107.4. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain variable region and a heavy chain variable region claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:91 claim 1 , and the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:92 claim 1 , 95 claim 1 , 97 claim 1 , 99 claim 1 , 101 claim 1 , 103 claim 1 , 105 claim 1 , and 107.5. The isolated anti-hemagglutinin antibody of claim 1 , wherein the antibody comprises a light chain comprising the amino ...

Anti-interleukin-33 antibodies and uses thereof.

La invención proporciona anticuerpos de interleucina-33 (IL- 33) y sus métodos de uso.

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti- hemagglutinin antibodies, and methods of using the same.

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.

Immunoglobulin variants and their applications

Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis.

La presente invención se refiere a prove métodos y reactivos útiles para detectar anticuerpos anti-fármaco de isotipo IgE para anticuerpos anti-IgE terapéuticos y métodos para determinar el riesgo de anafilaxis a la administración de un anticuerpo anti-IgE terapéutico.

Methods and compositions for the use of HIV env polypeptides and antibodies thereto

The Human Immunodeficiency Virus envelope protein or its fragments that are capable of binding to the T4 helper lymphocyte receptor are used in therapeutically effective doses for the treatment of immunoinflammatory disorders or diseases. Amino acid residues that constitue an essential portion of the T4 receptor binding domain of HIV env fall within a 64 residue sequence extending about from residues 411 to 454 of the 3B isolate. This domain is useful as a vaccine component, or for cytotoxic T cell targeting when conjugated with a target cell binding substance. HIV env which is devoid of a functional T4 receptor binding domain is useful as a vaccine for immunization against HIV infection. Antibodies capable of binding this domain also are provided for therapeutic and diagnostic use. An immunotoxin comprising a monoclonal antibody to a virally encoded cell surface antigen, linked to a toxin such as ricin A chain, is disclosed. Also, a method of killing virally infected cells such as HIV infected cells, comprising administering to the infected cells a therapeutically effective amount of the immunotoxin is disclosed.

ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME)

La invención proporciona anticuerpos de unión a CD20 humanizados mejorados para el tratamiento de células B malignas y enfermedades autos inmunes.

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Antibody variants and uses thereof

The invention provides improved humanized CD20 binding antibodies for treatment of B cell malignancies and autoimmune diseases.

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Immunoglobulin variants and uses thereof

The invention provides humanised and chimeric anti-CD20 antibodies for treatment of CD20 malignancies and autoimmune diseases.

METHODS AND COMPOSITIONS FOR THE USE OF ENV POLYPEPTIDES AND ANTI-ENV ANTIBODIES OF HIV.

LA PROTEINA DE FUNDA DE VIRUS DE INMUNODEFICIENCIA HUMANO, O SUS FRAGMENTOS, QUE SON CAPACES DE ENLAZAR AL RECEPTOR DE LINFOCITO DE REFUERZO T4, SON UTILES EN DOSIS TERAPEUTICAMENTE EFICACES PARA EL TRATAMIENTO DE DESORDENES O ENFERMEDADES INMUNOINFLAMATORIAS. LOS RESTOS DE AMINOACIDOS, QUE CONSTITUYEN PARTE ESENCIAL DEL DOMINIO DE UNION DEL RECEPTOR T4 DE FUNDA DE HIV CAEN DENTRO DE UNA SECUENCIA DE 64 RESTOS, QUE SE EXTIENDE DESDE 411 A 454 RESTOS DEL AISLADO 3B. ESTE DOMINIO ES UTIL COMO COMPONENTE DE VACUNA, O COMO BLANCO DE CELULAS T CITOTOXICAS CUANDO SE CONJUGA CON UNA SUSTANCIA ENLAZANTE DE CELULA BLANCO. LA FUNDA DE HIV, QUE ESTA LIBRE DE UN DOMINIO ENLAZANTE DE RECEPTOR T4 FUNCIONAL, ES UTIL COMO VACUNA PARA INMUNIZAR CONTRA LA INFECCION POR HIV. TAMBIEN SE PROPORCIONAN ANTICUERPOS CAPACES DE ENLAZAR ESTE DOMINIO PARA USO TERAPEUTICO Y DE DIAGNOSTICO. SE DESCRIBE UNA INMUNOTOXINA, QUE COMPRENDE UN ANTICUERPO MONOCLONAL PARA UN ANTIGENO DE SUPERFICIE CELULAR CODIFICADA VIRALMENTE. TAMBIEN SE DESCRIBE UN METODO PARA ELIMINAR CELULAS AFECTADAS VIRALMENTE, TALES COMO CELULAS HIV INFECTADAS, QUE CONSISTE EN ADMINISTRAR A LAS CELULAS INFECTADAS UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE LA INMUNOTOXINA. THE HUMAN IMMUNODEFICIENCY VIRUS CASE PROTEIN, OR ITS FRAGMENTS, WHICH ARE ABLE TO BIND THE T4 REINFORCEMENT LYMPHOCYTE RECEPTOR, ARE USEFUL IN THERAPEUTICALLY EFFECTIVE DOSE FOR TREATMENT OF IMMUNE DISEASES OR DISEASES. THE REMAINS OF AMINO ACIDS, WHICH CONSTITUTE AN ESSENTIAL PART OF THE UNION DOMAIN OF THE HIV CASE RECEIVER T4 FALL WITHIN A SEQUENCE OF 64 REMAINS, WHICH EXTENDS FROM 411 TO 454 REMAINS OF ISOLATE 3B. THIS DOMAIN IS USEFUL AS A VACCINE COMPONENT, OR AS A TARGET OF CYTOTOXIC T CELLS WHEN CONJUNCED WITH A WHITE CELL BINDING SUBSTANCE. THE HIV CASE, WHICH IS FREE OF A LINKING DOMAIN OF FUNCTIONAL T4 RECEIVER, IS USEFUL AS A VACCINE TO IMMUNIZE AGAINST HIV INFECTION. ANTIBODIES ABLE TO LINK THIS DOMAIN ARE ALSO PROVIDED FOR THERAPEUTIC AND DIAGNOSTIC ...

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti- hemagglutinin antibodies, and methods of using the same.

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti- hemagglutinin antibodies, and methods of using the same.

VARIATIONS OF IMMUNOGLOBULIN AND ITS USES.

Anticuerpo CD20 anti-humano o un fragmento de unión a antígeno del mismo, donde el anticuerpo comprende la secuencia VH de SEC ID No. 8 mostrada en la figura 1B (2H7.v16) y la secuencia VL de SEC ID No. 2 mostrada en la figura 1A (2H7.v16). Anti-human CD20 antibody or an antigen binding fragment thereof, wherein the antibody comprises the VH sequence of SEQ ID No. 8 shown in Figure 1B (2H7.v16) and the VL sequence of SEQ ID No. 2 shown in Figure 1A (2H7.v16).

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.

Anti-il-4 antibodies and bispecific antibodies and uses thereof

The invention provides anti-IL-4 antibodies and bispecific antibodies and methods of using the same.

Methods and compositions for the use of hiv env polypeptides and antibodies thereto

Abstract of the Disclosure The Human Immunodeficiency Virus envelope protein or its fragments that are capable of binding to the T4 helper lymphocyte receptor are used in therapeutically effective doses for the treatment of immunoinflammatory disorders or diseases. Amino acid residues that constitute an essential portion of the T4 receptor binding domain of HIV env fall within a 64 residue sequence extending about from residues 411 to 454 of the 3B isolate. This domain is useful as a vaccine component, or for cytotoxic T cell targeting when conjugated with a target cell binding substance. HIV env which is devoid of a functional T4 receptor binding domain is useful as a vaccine for immunization against HIV infection. Antibodies capable of binding this domain also are provided for therapeutic and diagnostic use. An immunotoxin comprising a monoclonal antibody to a virally encoded cell surface antigen, linked to a toxin such as ricin A chain, is disclosed. Also, a method of killing virally infected cells such as HIV infected cells, comprising administering to the infected cells a therapeutically effective amount of the immunotoxin is disclosed.

Anti-interleukin-33 antibodies and their uses.

La invención proporciona anticuerpos contra interleucina-33 (IL-33) y métodos de elaboración y uso de estos, por ejemplo, para el tratamiento de trastornos mediados por IL-33 (por ejemplo, trastornos oculares tales como AMD (por ejemplo, atrofia geográfica (GA)). The invention provides antibodies to interleukin-33 (IL-33) and methods of making and using these, for example, for the treatment of IL-33-mediated disorders (eg, ocular disorders such as AMD (eg, geographic atrophy). (GA)).

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis

Methods and preparations for the use of HIV env polypeptides and antibodies

isolated anti-hemagglutinin antibodies, method of treating, inhibiting or preventing infections, composition, pharmaceutical composition, isolated nucleic acid, host cell, antibody production method and use of anti-hemagglutinin antibody

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti- hemagglutinin antibodies, and methods of using the same.

Hiv envelope polypeptides

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.

Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis

The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.

IGE receptor antagonists

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Immunoglobulin variants and uses thereof

Cd20 antibody variants and uses thereof

The invention provides improved humanized CD20 binding antibodies for treatment of B cell malignancies and autoimmune diseases.

multispecific antibody, isolated antibody, isolated nucleic acid, host cell, antibody production method, immunoconjugate, pharmaceutical formulation, antibody use and method of treating individuals with disorder

resumo “anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio” a presente invenção fornece anticorpos anti-il-4, anticorpos biespecíficos e métodos de sua utilização. Summary "multispecific antibody, isolated antibody, isolated nucleic acid, host cell, antibody production method, immunoconjugate, pharmaceutical formulation, antibody use and method of treating disordered individuals" The present invention provides anti-il-4 antibodies, antibodies specific methods and methods of use.

Ige receptor antagonists

The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated FcεRI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides compositions, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.

Polypeptides that bind br3 and uses thereof

The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.

isolated antibodies, isolated nucleic acid, vector, host cell, method for producing antibody, composition, uses of an antibody and methods of treating a disorder

a invenção fornece anticorpos de interleucina-33 (il-33) e métodos de uso dos mesmos.

ANTIHEMAGLUTININE ANTIBODIES AND METHODS OF USE

La presente invención proporciona anticuerpos de antihemaglutinina, composiciones que comprenden anticuerpos de antihemaglutinina y sus métodos de uso.

Polypeptides That Bind Br3 and Uses Thereof

The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.

IMMUNOGLOBULIN VARIANTS AND USES THEREOF

VARIANTES D'IMMUNOGLOBULINE ET UTILISATIONS L'invention fournit les anticorps humanisés anti-CD20 et chimériques pour le traitement des malignancies CD20 positifs et des maladies auto-immunes. IMMUNOGLOBULIN VARIANTS AND USES The invention provides humanized anti-CD20 and chimeric antibodies for the treatment of CD20 positive malignancies and autoimmune diseases.

br3-binding antibodies or polypeptides, their uses and liquid formulations

ANTICORPOS OU POLIPEPTÍDEOS QUE SE LIGAM A BR3, SEUS USOS E FORMULAÇÕES LÍQUIDAS. A presente invenção refere-se a novos anticorpos e polipeptideos de ligação a BR3, incluindo polipeptídeos antagonistas e agonistas. A presente invenção também se refere ao uso dos anticorpos e polipeptídeos de ligação a BR3 em, por exemplo, métodos de tratamento, métodos de rastreamento, métodos de diagnóstico, ensaios e métodos de purificação de proteína. Antibodies or polypeptides that bind to BR3, their uses and liquid formulations. The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of BR3 binding antibodies and polypeptides in, for example, treatment methods, screening methods, diagnostic methods, assays and protein purification methods.

Immunoglobulin variants and uses thereof

Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis

Anti-interleukin-33 antibodies

La invención se relaciona con los anticuerpos anti-interleucina-33 (IL-33) y los métodos de uso estos. En algunas modalidades, el anticuerpo une específicamente IL-33 humana con una KD de entre alrededor de 100 fM y alrededor de 500 pM. En otras modalidades, el anticuerpo une específicamente IL-33 humana con una KD de entre alrededor de 1 pM y alrededor de 200 pM. La invención es útil en el tratamiento del cáncer. The invention relates to anti-interleukin-33 (IL-33) antibodies and the methods of using these. In some embodiments, the antibody specifically binds human IL-33 with a KD of between about 100 fM and about 500 pM. In other embodiments, the antibody specifically binds human IL-33 with a KD of between about 1 pM and about 200 pM. The invention is useful in the treatment of cancer.

Anti-influenza b virus hemagglutinin antibodies and methods of use.

La presente invención proporciona anticuerpos de hemaglutinina contra el virus de la influenza B, composiciones que comprenden anticuerpos de hemaglutinina contra el virus de la influenza B y sus métodos de uso.

Methods and preparations for the use of HIV env polypeptides and antibodies

The Human Immunodeficiency Virus envelope protein or its fragments that are capable of binding to the T4 helper lymphocyte receptor are used in therapeutically effective doses for the treatment of immunoinflammatory disorders or diseases. Amino acid residues that constitue an essential portion of the T4 receptor binding domain of HIV env fall within a 64 residue sequence extending about from residues 411 to 454 of the 3B isolate. This domain is useful as a vaccine component, or for cytotoxic T cell targeting when conjugated with a target cell binding substance. HIV env which is devoid of a functional T4 receptor binding domain is useful as a vaccine for immunization against HIV infection. Antibodies capable of binding this domain also are provided for therapeutic and diagnostic use. An immunotoxin comprising a monoclonal antibody to a virally encoded cell surface antigen, linked to a toxin such as ricin A chain, is disclosed. Also, a method of killing virally infected cells such as HIV infected cells, comprising administering to the infected cells a therapeutically effective amount of the immunotoxin is disclosed.

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

Immunoglobulin variants and uses thereof

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis

The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.

Immunoglobulin variants and uses thereof

The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.

Anti-interleukin-33 antibodies and uses thereof

La invención proporciona anticuerpos contra interleucina-33 (IL-33) y métodos de elaboración y uso de estos, por ejemplo, para el tratamiento de trastornos mediados por IL-33 (por ejemplo, trastornos oculares tales como AMD (por ejemplo, atrofia geográfica (GA)).  

Anti-influenza b virus hemagglutinin antibodies and methods of use

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same.

Anticuerpos anti-interleucina-33 y usos de estos.

La invención proporciona anticuerpos contra interleucina-33 (IL-33) y métodos de elaboración y uso de estos, por ejemplo, para el tratamiento de trastornos mediados por IL-33 (por ejemplo, trastornos oculares tales como AMD (por ejemplo, atrofia geográfica (GA)).

Immunoglobulinvarianten und deren verwendungen

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).

Anticuerpos de antihemaglutinina y metodos de uso.

La presente invención proporciona anticuerpos de antihemaglutinina, composiciones que comprenden anticuerpos de antihemaglutinina y sus métodos de uso.

Antagonisten des ige-rezeptors

NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES

Novel non-human primate FcεRIα polypeptides are provided. These receptor polypeptides are useful as agents for binding IgE, for example, in screening assays and in analysis of potency of anti-IgE drugs, and the like.

NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES

Novel non-human primate FcεRIα polypeptides are provided. These receptor polypeptides are useful as agents for binding IgE, for example, in screening assays and in analysis of potency of anti-IgE drugs, and the like.

Anti-interleukin-33 antibodies and uses thereof

The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for detection of IL-33 in biological samples.

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.

Anti-influenza B virus hemagglutinin antibodies and methods of use

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same.

Anti-hemagglutinin antibodies and methods of use

The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.